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OBJECTIVES: The pelvic floor muscles are sensitive to androgens, and due to hyperandrogenism, women with
polycystic ovary syndrome can have increased mass in these muscles compared to controls. The aim of this study is to
compare reports of urine leakage and quality of life between women with and without polycystic ovary syndrome.
METHODS: One hundred thirteen 18- to 40-year-old nulliparous women with polycystic ovary syndrome or without
the disease (controls) were recruited at the University Hospital of School Medicine of Sa˜o Paulo University at
Ribeira˜o Preto City, Brazil. The subjects were not taking any hormonal medication, had not undergone previous
pelvic surgery and did not exercise their pelvic floor muscles. The women were divided into the following four
groups: I- polycystic ovary syndrome with normal body mass index (n= 18), II- polycystic ovary syndrome with body
mass index $25 (n=32), III- controls with normal body mass index (n= 29), and IV- controls with Body Mass Index
$25 (n=34). Quality of life was evaluated using the SF-36 questionnaire, and the subjects with urinary complaints
also completed the International Consultation on Incontinence Questionnaire Short Form to evaluate the severity of
their urinary incontinence.
RESULTS: The replies to the International Consultation on Incontinence Questionnaire Short Form revealed a
significant difference in urinary function between groups, with 24% of the subjects in group IV reporting urinary
incontinence. The mean scores for the SF-36 questionnaire revealed that group II had the lowest quality of life.
CONCLUSIONS: The control obese group (IV) reported a higher prevalence of urinary incontinence. There was no
difference in the reported frequency of urine loss between the polycystic ovary syndrome and control groups with
normal body mass index or between the polycystic ovary syndrome and control groups with body mass index $25.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in women of reproductive
age, affecting an average of seven percent of all women of
reproductive age. PCOS is associated with clinical and
biochemical hyperandrogenism, menstrual irregularities,
and acne.1,2
It is commonly known that the use androgens and anabolic
steroids increases muscle mass and strength. Because of the
characteristics of obesity and hyperandrogenism in PCOS, it
is plausible that women with PCOS may have an increased
muscle mass relative to controls. Anthropometric character-
istics, including excess fat mass, percent body fat, and body
fat androgen distribution, have been well documented in
PCOS.3 However, only a limited amount of information is
available regarding the possible connection between PCOS
and increased muscle mass in general.3
The association between obesity and PCOS was first
described by Stein and Leventhal.4 Obesity among women
with PCOS has implications for general health and is also a
risk factor for pelvic floor dysfunction.5,6 Obesity can
increase intra-abdominal pressure and thus expose the
pelvic support structures and organs to a chronic state of
stress, with subsequent pelvic floor muscle fatigue and/or
chronic stretch of the pudendal nerve.7 According to some
studies, these structures are important for the maintenance
of urinary continence; therefore, obesity represents a risk
factor for urinary incontinence (UI).8-10
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Recent studies have shown that androgens may poten-
tially play an important role in changes in the pelvic floor
and lower urinary tract, as the muscles in these structures—
particularly the levator ani and the urethral sphincter—are
sensitive to androgens.11,12
Urinary incontinence is a common health problem among
women and is highly prevalent in older women; however,
according to some studies, urinary incontinence is unex-
pectedly prevalent among young females as well.13-15
Ha¨gglund et al13 investigated the prevalence of urinary
incontinence among females with a special focus on
younger women, and their principal finding was that
urinary incontinence was reported by 23% of nulliparous
women, with one-eighth of women below 30 years of age
reporting problems with urinary incontinence.
Polycystic ovary syndrome (PCOS) typically manifests
during the reproductive period, and no information is
available on the prevalence of pelvic floor dysfunction (and
urinary incontinence in particular) among women with
PCOS.
Because there is a high incidence of obesity among
women with PCOS, two counteracting variables might
affect the function of the pelvic floor muscles and cause
problems related to this function, including UI. These
variables are obesity itself as a source of overload on the
muscles of the pelvic floor and hyperandrogenism as a
factor that is likely to improve the function of the pelvic
floor muscles. In light of the paucity of previous studies
regarding this topic, the objective of the present investiga-
tion was to assess UI rates, symptoms of urine loss and
quality of life in obese and non-obese women with PCOS
and to compare these findingm to obese and non-obese
women without PCOS.
MATERIALS AND METHODS
We conducted an observational cross-sectional controlled
study at the University Hospital, Faculty of Medicine of
Ribeira˜o Preto, University of Sa˜o Paulo (HC-FMRPUSP).
The project was approved by the Research Ethics
Committee of HC-FMRP (protocol no. HCRP 11165/2007),
and each subject provided written informed consent prior to
her participation.
The study included a sample of 113 women with PCOS
and controls who were seen at this institution; they were
divided into the following four groups: group I consisted of
18 women with normal body mass index (BMI) (between
18.5 and 24.9 kg/m2) and PCOS; group II consisted of 32
overweight or obese women (BMI 25 to 39.9 kg/m2) with
PCOS; group III consisted of 29 women without PCOS and
with normal BMI; and group IV consisted of 34 women
without PCOS and with BMI $25 kg/m2.
Subjects
The diagnosis of PCOS was based on the criteria of the
2003 Rotterdam Consensus,16 as used by the Department of
Endocrine Gynecology, HC-FMRP-USP. The following
inclusion criteria were applied: nulliparous women age 18
to 40 years, no previous pelvic surgery or pregnancy, not
engaged in training of pelvic floor muscles, and not using
any hormonal medicine that could influence the muscle. We
also excluded women with an androgen-secreting neo-
plasm, pituitary adenoma, adrenal hyperplasia, acromegaly
or Cushing’s syndrome.
Women with PCOS had clinical or biochemical hyperan-
drogenism, and the control women had normal ovulatory
cycles (which ranged from 26 to 33 days).
Evaluation
Each subject completed the International Consultation on
Incontinence Questionnaire (ICIQ-SF) to assess her UI
symptoms; the questionnaire was validated and translated
into Portuguese. Women who reported an involuntary loss
of urine one or more times per week over the preceding
three months were classified as incontinent.17
Each participant also completed a questionnaire to assess
her health-related quality of life (SF-36), and the incon-
tinent women additionally completed the International
Consultation on Incontinence Questionnaire-Short Form
(ICIQ-SF), which is a specific questionnaire that assesses
the severity of UI symptoms. The ICIQ-SF consists of six
questions on the subject’s reports of urinary incontinence
during the previous four weeks. Based on the responses to
Q3, Q4, and Q5, a score is calculated from the sum of the
score for each answer; this score ranges from zero (when
there is no report of urine leakage, reflecting no impact on
the quality of life) to 21 (highest severity of UI and the
maximum impact on the quality of life). Based on the mean
scores for Q3, Q4, and Q5, Klovning et al.18 classified the
index of severity of UI and related QOL into the following
five levels: slight (1-5), moderate (6-12), severe (13 -18), and
highly severe (19-21).
The SF-36 is a widely used and validated instrument that
includes the following eight domains: functional capacity,
limitation of physical aspects, pain, general health, vitality,
social aspects, emotional aspects, and mental health. These
eight domains range from 0 (zero) to 100 (one-hundred),
where 0 =worst and 100= best score for each domain.19
Statistical Analysis
We analyzed the data using the PROC MEANS and
PROC FREQ features of the SAS 9.0 software program. A
quantile regression model was used to analyze the
quantitative variables20 to compare the median K values
between the various groups of interest. The results were
obtained using the STATA software program.
The qualitative variables were analyzed with the Fisher’s
exact test using the SAS 9.0, PROC FREQ software program.
RESULTS
The mean age (and range) was 24.78 years (18-32) for
group I, 28.75 years (18-38) for group II, 31.69 (23-39) years
for group III, and 30.61 (21-38) for group IV. Groups II and
IV were similar with respect to age (p= 0.32), whereas
groups I and III were not (p,0.01). The groups were similar
with respect to skin color (p= 0.63).
Table 1 shows the prevalence of UI in the four groups.
Group IV had the highest prevalence (24%) of urinary loss
and was followed by groups III, II, and then I. The Fisher’s
exact test revealed a difference between all four of the
groups (p= 0.04). However, when the groups with similar
BMI were examined (Table 2), we found no significant
difference between groups I and III (p= 0.52) or between
groups II and IV (p= 0.08).
An analysis of the ICIQ-SF results revealed no statistically
significant differences between the groups with regard to
the severity of the urinary complaints.
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Table 3 summarizes the average values that were obtained
for each domain of the SF-36 in each of the various groups.
Group II had the lowest averages with regard to functional
capacity, limitation of physical aspects, pain, general health,
vitality, social aspects, and mental health. A comparison of
groups II and IV using the quantile regression model
revealed significant differences in the functional capacity
(p,0.02), general health (p,0.01) and social aspects (p,0.01)
domains.
DISCUSSION
In the present study, we investigated the hypothesis that
hyperandrogenism in women with PCOS might act as a
protective factor against UI. This hypothesis was based on
studies reporting that androgens can play an important role
in changes in the pelvic floor and in the lower urinary tract,
as the muscles of these structures—in particular, the levator
ani and the urethral sphincter—express high number of
androgen receptors and are therefore sensitive to andro-
gens.11,12,21,22 In addition, androgen receptors are present in
the smooth muscle of various female urogenital tissues,
thereby suggesting the importance of androgens in the
lower urinary tract.23
In a 2011 study, Mammadov et al24 verified the effect of
testosterone treatment on the urodynamic findings and
histopathomorphology of the pelvic floor muscle in female
rats with experimental stress-induced urinary incontinence.
These authors observed that after testosterone administration,
there were increases both in pressure loss in the urodynamics
findings and in the muscle’s cross-sectional area.
Although the aforementioned hypothesis is plausible, the
present study is the first to compare the frequency of reports
of urine loss between women with and without PCOS. To
help compensate for the effects of BMI, we investigated
women with and without PCOS who were divided into
groups of BMI that were ,25 or $25. The two PCOS groups
reported UI less frequently than did the control groups. The
first analysis revealed a difference between the four groups;
however, this difference disappeared when the groups were
analyzed according to BMI. The difference between the four
groups was due to the fact that the women with BMI $25
reported UI more frequently, and this effect was especially
true in the group without PCOS. In this respect, these
findings agree with previous reports that indicate that being
overweight (and obesity in particular) has a negative effect
on the structures of the pelvic floor by weakening the
muscles and fascia that are important for maintaining
continence and by possibly causing neurologic damage
and increased intra-abdominal pressure.7 Thus, obesity is a
risk factor for the development of UI.8-10
The women in the control group with BMI $25 reported
the highest prevalence of UI (24% of the women in this
group) and presented the highest frequency of urine loss,
the highest impact of urine loss on daily life and the highest
number of activities that were affected by this loss.
An analysis of the results of the quality of life ques-
tionnaire (SF-36) revealed that the PCOS group with BMI
$25 reported the lowest mean values with regard to
functional capacity, limitation of physical aspects, pain,
general health status, vitality, social aspects, and mental
health. These results may be explained by previous studies
that demonstrated that PCOS involves some risk factors for
the development of cardiovascular disease, such as insulin
resistance, dyslipidemia, diabetes mellitus, systemic arterial
hyeon, endothelial dysfunction, central obesity, chronic pro-
inflammatory markers, systemic arterial hypertension, and
poor physical fitness.5,25,26 A non-dipping blood pressure
(BP) pattern can be considered to be an independent
predictor of future cardiovascular events. A recent cross-
sectional study by Kargili and collaborators27 was per-
formed to identify any relationship between changes in BP
patterns during sleep and PCOS. Their study revealed that a
non-dipping BP pattern is highly prevalent among PCOS
patients. This condition contributes to the risk of developing
cardiovascular disease in women with PCOS and to a
subsequent decrease in the quality of life.
These factors, together with the other risk factor, obesity,
tend to impair the quality of life of women with PCOS and
with a BMI $25.5,28
According to a review by Spritzer,29 women with
hirsutism—which is highly prevalent among women with
PCOS—experience marked psychosocial discomfort that
Table 1 - Prevalence of incontinence among the women in the four groups, and the association of the groups with
reports of urinary incontinence.
Groups n
Women with urinary loss
(N)
Percentage of women
with urinary loss p-value
I- PCOS with normal BMI 18 0 0%
II- PCOS with BMI $25 kg/m2 32 2 6% 0.04
III- Control with normal BMI BMI 29 2 7%
IV- Control with BMI $25 kg/m2 34 8 24%
Table 2 - Comparison of the groups with the same BMI using the Fisher’s exact test.
Groups Urinary complaints
Total
n p-value
No Yes
n % n %
I- PCOS with normal BMI 18 0% 100% 0 0 0% 0 18
III- Control with normal BMI 27 93% 93%% 2 7% 7 29 0.52
II- PCOS with BMI $25 kg/m2 30 94% 94 2 6% 6 32
IV- Control with BMI $25 kg/m2 26 76% 76 8 24% 24 34 0.08
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leads to conflicts that compromise their quality of life; we
observed this situation in the present study as well.
The general quality of life that was evaluated in these
women might not depend on UI, as several aspects were
evaluated, and several studies that did not assess UI also
indicated a poorer general quality of life among obese
women with PCOS.
The hypothesis that PCOS may serve a protective role
against UI is not supported by the present findings. However,
some limitations of the present study should be discussed,
and the most important of these is the fact that a convenience
sample was used that only included nulliparous women. On
one hand, this choice controlled the parity variable, which is
known to be related toUI; on the other hand, the prevalence of
UI among nulliparous women is much lower than among
parous women. It should also be noted that, even though a
validated instrument was used to assess the report of UI and
although all interviews were conducted by one examiner,
several studies have indicated that UI tends to be under-
reported.30,31 This effect may explain the seemingly small
number of affected patients in this study, and it represents a
limitation.Moreover, the stringent inclusion criteriamay have
also contributed to the small sample size.
It is also important to note that a physical examination
was not performed. This omission represents another
limitation of this study because a symptom-based diagnosis
can underestimate the true presence of urinary incontinence
when diagnosed by physical examination.
Despite these limitations, this first report should serve as
the basis for future studies with representative stratified
samples of nulliparous and multiparous women in which
reports of UI can be correlated to androgen levels and PFM
to clarify the impact of PCOS on these variables.
A higher percentage of obese women in the control (non-
PCOS) group reported UI. There was no difference in the
frequency of reports of urine loss between the PCOS group
with normal BMI and its control group with normal BMI, nor
between the PCOS group with BMI$25 and its control group
with BMI$25. The quality of life of women with PCOS and
BMI$25 is lower than that of women without PCOS.
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